Correction: Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy (Annals of Neurology, (2023), 93, 6, (1173-1186), 10.1002/ana.26610)

Following the publication of our article,¹ we noticed that there was an error. The combinations of amyloid β (Aβ) peptides that result in the highest areas under the curve (AUCs) to discriminate patients with sporadic cerebral amyloid angiopathy (sCAA) from patients with Alzheimer disease (AD) are different than stated in the original article. This is mentioned three times in the article. Below are the three sentences that should be corrected. The following sentence in the Results section (under the paragraph heading “CSF Aβ Levels in Patients with AD Compared to Patients with sCAA and Controls: Validation Group”): “The combination of CSF Aβ40 and Aβ43 in combination with either Aβ38 or Aβ42 both yielded the highest AUC (0.96, 95% CI = 0.92–1.0)” should be changed to: “The combination of CSF Aβ42 and CSF Aβ43 with either Aβ38 or Aβ40 yielded the highest AUCs (0.96, 95% CI = 0.91–1.0, and 0.96, 95% CI = 0.92–1.0, respectively).” The following sentence in first paragraph of the Discussion: “The combination of Aβ40, Aβ43, and either Aβ38 or Aβ42 yielded an AUC of 0.96 to discriminate sCAA from AD patients” should be changed to: “The combination of Aβ42, Aβ43, and either Aβ38 or Aβ40 yielded an AUC of 0.96 to discriminate sCAA from AD patients.” The following sentence in the fifth paragraph of the Discussion: “However, we show that the combination of Aβ40, Aβ43, and either Aβ38 or Aβ42 yielded an AUC of 0.96 to discriminate sCAA from AD” should be changed to: “However, we show that the combination of Aβ42, Aβ43, and either Aβ38 or Aβ40 yielded an AUC of 0.96 to discriminate sCAA from AD.” We regret and sincerely apologize for the error.